SEC Form SC 14D9/A filed by Miromatrix Medical Inc. (Amendment)

$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $MIRO alert in real time by email
SC 14D9/A 1 tm2332676d2_sc14d9a.htm SC 14D9/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

 

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

 

 

Miromatrix Medical Inc.

(Name of Subject Company)

Miromatrix Medical Inc.

(Name of Persons Filing Statement)

 

 

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

 

60471P108

(CUSIP Number of Class of Securities)

 

John S. Hess, Jr., Esq.

Executive Vice President and Deputy General Counsel
6455 Flying Cloud Drive, Suite 107
Eden Prairie, MN 55344

(952) 942-6000

(Name, address, and telephone numbers of person authorized to receive notices and communications

on behalf of the persons filing statement)

 

With copies to:

 

Stephen Glover, Esq.

Alexander Orr, Esq.

Gibson, Dunn & Crutcher LLP

1050 Connecticut Avenue, N.W.

Washington, D.C. 20036

(202) 955-8500

 

  Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

 

 

This Amendment No. 4 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 of Miromatrix Medical Inc., a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023 (as amended or supplemented from time to time, the “Recommendation Statement”), relating to the tender offer by Morpheus Subsidiary Inc. (“Purchaser”), a Delaware corporation and a wholly owned subsidiary of United Therapeutics Corporation (“Parent”), a Delaware public benefit corporation, to purchase all of the outstanding shares of common stock of the Company, par value $0.00001 per share (the “Shares”), for (a) $3.25 per Share in cash, plus (b) one contractual contingent value right per Share, representing the right to receive a contingent payment of $1.75 in cash upon the achievement of a specified milestone on or prior to December 31, 2025, upon the terms and subject to the conditions set forth in the offer to purchase, dated as of November 13, 2023 (the “Offer to Purchase”), and in the related letter of transmittal (the “Letter of Transmittal,” which, together with the Offer to Purchase and other related materials, as each may be amended, supplemented or otherwise modified from time to time, collectively constitute the “Offer”).

 

Capitalized terms used in this Amendment but not defined herein shall have the respective meanings given to such terms in the Recommendation Statement. The information set forth in the Recommendation Statement remains unchanged and is incorporated herein by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein. Underlined text shows text being added to a referenced disclosure in the Recommendation Statement and stricken-through text shows text being deleted from a referenced disclosure in the Recommendation Statement.

 

Item 8. Additional Information.

 

Item 8(h) of the Recommendation Statement is hereby amended and supplemented as follows:

 

(h) Final Results of the Offer and Expected Completion of the Merger.

 

The Offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023 (such date and time, the “Expiration Date”). Continental Stock Transfer & Trust Company, in its capacity as Paying Agent for the Offer, advised that, as of the Expiration Date, a total of 22,876,102 Shares were validly tendered and “received” (as defined in Section 251(h) of the DGCL) by the Paying Agent and not validly withdrawn pursuant to the Offer, which Shares, together with all other Shares beneficially owned by Purchaser and its affiliates, represent approximately 83.43% of the Shares outstanding as of the Expiration Date. As of the Expiration Date, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer, together with all other Shares beneficially owned by Purchaser and its affiliates, satisfied the Minimum Condition. After the expiration of the Offer, Purchaser irrevocably accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer. Purchaser will promptly pay for all such Shares.

 

As the final step of the acquisition process, Parent expects to completed its acquisition of the Company by consummating the Merger on December 13, 2023, in accordance with Section 251(h) of the DGCL, without a vote of the Company’s stockholders. At the Effective Time, Purchaser will be merged with and into the Company, the separate existence of Purchaser will ceased, and the Company will continued as the Surviving Corporation and a wholly owned subsidiary of Parent. Each issued and outstanding Share immediately before the Effective Time (other than (i) any Excluded Shares and (ii) any Dissenting Shares) will be converted into the right to receive the Offer Consideration from Purchaser.

 

As a result of the Merger, the Shares will be delisted and will cease to trade on the Nasdaq Capital Market. Parent and Purchaser intend to take steps to cause the termination of the registration of the Shares under the Exchange Act and to suspend all of the Company’s reporting obligations under the Exchange Act as promptly as practicable.

 

On December 12, 2023, Parent and the Company issued a joint press release announcing the expiration and results of the Offer. The full text of the press release is included as Exhibit (a)(5)(D) hereto and is incorporated herein by reference.

 

On December 13, 2023, Parent and the Company issued a joint press release announcing the completion of the Merger. The full text of the press release is included as Exhibit (a)(5)(E) hereto and is incorporated herein by reference.

 

 

 

 

 

Item 9. Exhibits.

 

Item 9 of the Recommendation Statement is hereby amended by adding the following exhibit.

 

Exhibit No.   Description
     
(a)(5)(E)   Press Release, dated December 13, 2023.

 

 

 

 

SIGNATURE

 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: December 13, 2023 MIROMATRIX MEDICAL INC.
   
  By: /s/ John S. Hess, Jr.
  Name: John S. Hess, Jr.
  Title: Executive Vice President, Deputy General Counsel, and Assistant Corporate Secretary

 

 

 

Get the next $MIRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MIRO

DatePrice TargetRatingAnalyst
7/19/2021$22.00Buy
Craig Hallum
More analyst ratings

$MIRO
Press Releases

Fastest customizable press release news feed in the world

See more
  • United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

    United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

    United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Miromatrix Reports Third Quarter 2023 Results

    EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$MIRO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MIRO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MIRO
SEC Filings

See more

$MIRO
Leadership Updates

Live Leadership Updates

See more
  • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

    DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

    $AXGN
    $MIRO
    $VRAY
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Miromatrix Appoints Jack Lake, M.D., as Medical Director

    EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Miromatrix Names Jim Douglas as New Chief Financial Officer

    EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$MIRO
Financials

Live finance-specific insights

See more
  • Miromatrix Reports Third Quarter 2023 Results

    EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

    EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Miromatrix to Report Second Quarter 2023 Financial Results

    EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$MIRO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more